glp-1 agonists diabetes New Guidelines for Type 2 in 2025 GLP-1-based therapies for type 2
Description
This update was prepared for World Obesity Day 2026
Milestones in Glucose Homeostasis: A Foundation for GLP-1R Agonist Development Studies have shown that oral glucose intake elicits a more robust insulin secretion response compared to intravenous glucose delivery, despite identical glucose concentrations [3]
Pr G.-D
Particularly where obesity rather than diabetes is the main target
Tirzepatide acts as a GIP analog, meaning it mimics the actions of GIP to further improve insulin release
